Adherence to Palivizumab Prophylaxis
Behavioral Interventions to Increase Adherence to Palivizumab Prophylaxis in Children With Congenital Heart Disease: A Randomized Controlled Trial
1 other identifier
interventional
229
1 country
1
Brief Summary
The goal of this clinical trial is to analyze implications of two alternative nudge-interventions to increase adherence to palivizumab prophylaxis in children with congenital heart disease. The main questions investigators aim to answer are:
- Are well-established cognitive biases effective in increasing patient families' adherence to the palivizumab prophylaxis program?
- What are the factors that affect families' adherence to the prophylaxis program and whether and how the effects of interventions depend on these factors? To study these questions investigators planned to utilize four well-established cognitive biases in designing two alternative nudge-interventions and investigators measured the effectiveness of each nudge-intervention against a control group. Patients were randomly allocated to one control and two treatment groups. In the control group, investigators informed participants about the prophylaxis program and provided a schedule. Patients in the first treatment group were additionally called two days before appointments (status quo bias), and were asked to plan the appointment day (implementation intention). Patients in the second treatment group received biweekly messages informing them about the benefits of the program as well as the current adherence rate (availability bias and social norm).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2021
CompletedFirst Submitted
Initial submission to the registry
February 17, 2023
CompletedFirst Posted
Study publicly available on registry
March 21, 2023
CompletedMarch 21, 2023
March 1, 2023
3 months
February 17, 2023
March 18, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Effectiveness of cognitive biases in increasing adherence to prophylaxis programme
The average adherence rates in the control and treatment groups
4 weeks
Secondary Outcomes (17)
The effect of father employment status (full-time, part-time, no) on the participants' adherence to the prophylaxis program
8 weeks
The effect of number of children in the family on the participants' adherence to the prophylaxis program
8 weeks
The effect of birth weight (weight in grams) on the participants' adherence to the prophylaxis program
8 weeks
The effect of number of intensive care unit admissions on the participants' adherence to the prophylaxis program
8 weeks
The effect of knowledge about respiratory syncytial virus previously (yes/no) on the participants' adherence to the prophylaxis program
8 weeks
- +12 more secondary outcomes
Study Arms (3)
Status quo bias and implementation intention bias
EXPERIMENTALParticipants' families in this arm were informed about prophylaxis program and provided a schedule additionally called two days before appointments (status quo bias) and were asked to plan the appointment day (implementation intention).
Availability bias and social norm
EXPERIMENTALParticipants' families in this arm were informed about prophylaxis program and provided a schedule and were received messages biweekly informing about benefits of program and adherence rate (availability bias and social norm).
Control
EXPERIMENTALParticipants' families in this arm were informed about prophylaxis program and provided a schedule
Interventions
Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions. 1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace? 2. What kind of transportation do you plan to take to come to the hospital at your appointment day? 3. At what time do you plan to leave home or work to come to the hospital?
Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
Eligibility Criteria
You may qualify if:
- Diagnosis of congenital heart disease which are hemodynamically unstable, congestive heart failure, diagnosis of congenital heart disease with hemodynamically significant residual defects after corrective heart surgery, cardiomyopathy, pulmonary hypertension
- Being between 0-2 years of age
You may not qualify if:
- Diagnosis of congenital heart disease in which palivizumab prophylaxis is not needed (the diagnosis of congenital heart diseases which are hemodinamically stable.)
- Becoming exitus during prophylaxis program
- Not being between 0-2 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kosuyolu Heart Hospitallead
- Sabanci Universitycollaborator
- Maras Necip Fazil City Hospitalcollaborator
- Kocaeli Universitycollaborator
- Van Research and Education Hospitalcollaborator
- Sakarya Universitycollaborator
- Sivas Numune Hospitalcollaborator
Study Sites (1)
Kosuyolu Heart Hospital
Istanbul, Turkey (Türkiye)
Related Publications (1)
Erolu E, Kibris O, Tosun Y, Yildirim A, Pamukcu O, Basar EZ, Babaoglu K, Epcacan S, Donmez Y, Giray D, Dervisoglu P, Tasci O. Behavioural interventions to increase adherence to palivizumab prophylaxis in children with CHD. Cardiol Young. 2024 Apr 26:1-8. doi: 10.1017/S1047951124024946. Online ahead of print.
PMID: 38664919DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Elif Erolu, M.D.Ph.D.
Kosuyolu Heart Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
February 17, 2023
First Posted
March 21, 2023
Study Start
October 1, 2020
Primary Completion
December 31, 2020
Study Completion
June 1, 2021
Last Updated
March 21, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share